<DOC>
	<DOC>NCT01013116</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of specific subcutaneous immunotherapy with modified allergen extracts.</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Positive history of perennial allergic rhinitis due to house dust mites Positive screening skin prick test (wheal diameter &gt; 3 mm) Compliance and ability of the patient to complete a Diary Card for selfevaluating of the symptoms and antisymptomatic medication Signed and dated patient´s Informed Consent, Previous immunotherapy with mite extracts within the last 3 years, Simultaneous participation in other clinical trials, Other reasons contraindicating an inclusion into the trial according to the investigator´s estimation (e.g. poor compliance), Autoimmune disorders, Severe chronic inflammatory diseases, Malignancy, Alcohol abuse, Existing or intended pregnancy, lactation and/or lack of adequate contraceptive protection, Treatment with betablockers (incl. local application) and/or other contraindicated drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>